{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:14:08Z","timestamp":1789708448140,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000936","name":"Gordon and Betty Moore Foundation","doi-asserted-by":"publisher","award":["GBMF7853"],"award-info":[{"award-number":["GBMF7853"]}],"id":[{"id":"10.13039\/100000936","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jval.2020.09.021","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:06:54Z","timestamp":1617235614000},"page":"759-769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios"],"prefix":"10.1016","volume":"24","author":[{"given":"Thomas F.","family":"Broekhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly C.G.","family":"Sweegers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline M.","family":"Krijkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aukje K.","family":"Mantel-Teeuwisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert G.M.","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim G.","family":"Goettsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick A.","family":"Vreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"71","key":"10.1016\/j.jval.2020.09.021_bib1","first-page":"1","article-title":"Spinal muscular atrophy","volume":"6","author":"Amico","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jval.2020.09.021_bib2","series-title":"Pakketadvies nusinersen bij SMA","year":"2018"},{"issue":"5","key":"10.1016\/j.jval.2020.09.021_bib3","doi-asserted-by":"crossref","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","article-title":"Survival of patients with spinal muscular atrophy type 1","volume":"131","author":"Gregoretti","year":"2013","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.jval.2020.09.021_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.jval.2020.09.021_bib5","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2020.09.021_bib7","series-title":"Spinraza and Zolgensma for spinal muscular atrophy: effectiveness and value","author":"Ellis","year":"2019"},{"issue":"12","key":"10.1016\/j.jval.2020.09.021_bib8","first-page":"1300","article-title":"The effectiveness and value of treatments for spinal muscular atrophy","volume":"25","author":"Pearson","year":"2019","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"18","key":"10.1016\/j.jval.2020.09.021_bib10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jval.2020.09.021_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"10.1016\/j.jval.2020.09.021_bib12","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.ymthe.2018.10.017","article-title":"Addressing the value of gene therapy and enhancing patient access to transformative treatments","volume":"26","author":"Salzman","year":"2018","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jval.2020.09.021_bib15","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Malone","year":"2019","journal-title":"J\u00a0Mark Access Heal Policy"},{"issue":"1","key":"10.1016\/j.jval.2020.09.021_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2020.09.021_bib17","author":"Mathias"},{"issue":"3","key":"10.1016\/j.jval.2020.09.021_bib19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0272989X18754513","article-title":"Microsimulation modeling for health decision sciences using R: a tutorial","volume":"38","author":"Krijkamp","year":"2018","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.jval.2020.09.021_bib26","series-title":"Nusinersen for treating spinal muscular atrophy: A Single Technology Appraisal","author":"Tappenden","year":"2018"},{"issue":"139","key":"10.1016\/j.jval.2020.09.021_bib30","first-page":"1","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jval.2020.09.021_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2020.09.021_bib23","series-title":"Guideline for economic evaluations in healthcare","first-page":"1","year":"2016"},{"key":"10.1016\/j.jval.2020.09.021_bib24","author":"Arts"},{"issue":"9","key":"10.1016\/j.jval.2020.09.021_bib25","doi-asserted-by":"crossref","first-page":"A725","DOI":"10.1016\/j.jval.2017.08.1962","article-title":"The utility of different approachs to developing health utilities data in childhood rare diseases: a case study in spinal muscular atrophy (SMA)","volume":"20","author":"Thompson","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2020.09.021_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-016-0424-0","article-title":"Disease burden of spinal muscular atrophy in Germany","volume":"11","author":"Klug","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.jval.2020.09.021_bib31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","article-title":"A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients","volume":"146","author":"Zerres","year":"1997","journal-title":"J\u00a0Neurol Sci"},{"issue":"25","key":"10.1016\/j.jval.2020.09.021_bib32","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.jacc.2008.09.018","article-title":"Interpreting the results of cost-effectiveness studies","volume":"52","author":"Cohen","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jval.2020.09.021_bib33","series-title":"National Institute for Health and Clinical Excellence The Guidelines Manual","year":"2012"},{"key":"10.1016\/j.jval.2020.09.021_bib34","series-title":"Cost-effectiveness in practice","author":"van Saasse","year":"2015"},{"issue":"3","key":"10.1016\/j.jval.2020.09.021_bib40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.healthpol.2017.11.012","article-title":"Funding breakthrough therapies: a systematic review and recommendation","volume":"122","author":"Hanna","year":"2018","journal-title":"Health Policy (New York)"},{"issue":"1","key":"10.1016\/j.jval.2020.09.021_bib41","first-page":"1","article-title":"Annuity payments can increase patient access to innovative cell and gene therapies under England\u2019s net budget impact test","volume":"5","author":"J\u00f8rgensen","year":"2017","journal-title":"J\u00a0Mark Access Health Policy"},{"issue":"1","key":"10.1016\/j.jval.2020.09.021_bib42","first-page":"1","article-title":"Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer","volume":"20","author":"Clopes","year":"2017","journal-title":"J\u00a0Med Econ"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152100053X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152100053X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:22:06Z","timestamp":1761096126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830152100053X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S109830152100053X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.09.021","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}